Taken together, these studies provide a compelling evidence that targeting p53 inhibitors can augment therapeutic benefits of p53-mediated tumor cell killing via engagement of both innate and adaptive anti-tumor immune responses to achieve durable and systemic tumor eradication. This evidence concerns the gene TP53 and neoplasm.